77205
document
Chemotherapy with cyclophosphamide , doxorubicin , vincristine , and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma : a Southwest Oncology Group Study . Between 1977 and 1983 the Southwest Oncology Group ( SWOG ) evaluated chemotherapy alone ( cyclophosphamide , doxorubicin , vincristine , prednisone ; CHOP ) or chemoimmunotherapy ( CHOP-levamisole or CHOP-levamisole-BCG ) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma ( ML ) . Of 281 evaluable patients with favorable histologic types of ML , 171 ( 61 % ) achieved complete remission ( CR ) and there was no difference in CR rate , CR duration , or survival according to the type of initial treatment . Of 388 evaluable patients with unfavorable histologic types of ML , 194 ( 50 % ) achieved CR . Levamisole appeared to adversely affect CR rates in nodular mixed and nodular large-cell lymphoma and CR duration in patients with unfavorable histology ML . Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates , CR duration , or survival compared to CHOP chemotherapy alone , and levamisole may have had an adverse impact on outcome in certain subtypes of ML .
77206
Intervention_Pharmacological
Chemotherapy with cyclophosphamide , doxorubicin , vincristine , and prednisone alone or with levamisole or with levamisole plus BCG for
77207
Intervention_Pharmacological
chemotherapy alone ( cyclophosphamide , doxorubicin , vincristine , prednisone ; CHOP )
77208
Intervention_Pharmacological
chemoimmunotherapy ( CHOP-levamisole or CHOP-levamisole-BCG )
77209
Intervention_Pharmacological
Levamisole
77210
Intervention_Pharmacological
Chemoimmunotherapy with levamisole or levamisole-BCG
77211
Intervention_Physical
CHOP chemotherapy
77212
Intervention_Pharmacological
levamisole
77213
Outcome_Physical
complete remission ( CR )
77214
Outcome_Physical
CR rate , CR duration , or survival
77215
Outcome_Physical
CR
77216
Outcome_Other
.
77217
Outcome_Mortality
CR rates
77218
Outcome_Physical
CR duration
77219
Outcome_Mortality
CR rates
77220
Outcome_Adverse-effects
,
77221
Outcome_Mortality
CR duration ,
77222
Outcome_Adverse-effects
or
77223
Outcome_Mortality
survival
77224
Participant_Sample-size
715
77225
Participant_Condition
malignant lymphoma
77226
Participant_Sample-size
281
77227
Participant_Condition
ML
77228
Participant_Sample-size
388